Dial 9-1-1 for p53: Mechanisms of p53 activation by cellular stress

Neoplasia

Volumn 2, Issue 3, 2000, Pages 208-225

  Ljungman, Mats ^a  

^a UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

Author keywords

Blocked RNA polymerase II; MDM2; Nucleocytoplasmic shuttling; Phosphorylation; Proteasome

Indexed keywords

GENE PRODUCT; PROTEIN P53;

ARTICLE; DNA DAMAGE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TRANSLATION REGULATION; TUMOR SUPPRESSOR GENE;

EID: 0034039040     PISSN: 15228002     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.neo.7900073     Document Type: Article

References (290)

1. Levine AJ (1997). p53, the cellular gatekeeper for growth and division. Cell 88, 323-331.
2. Ziegler A, Jonason AS, Leffell DJ, Simon JA, Sharma HW, Kimmelman J, Remington L, Jacks T, and Brash DE (1994). Sunburn and p53 in the onset of skin cancer. Nature 372, 773-776.
3. Baker S, Preisinger A, Jessup J, Paraskeva C, Markowitz S, Wilson J, Hamilton S, and Vogelstein B (1990). p53 gene mutations occur in combination with 17p allelic deletions as late events in colorectal tumorigenesis. Cancer Res 50, 7717-7722.
4. Fisher DE (1994). Apoptosis in cancer therapy: crossing the threshold. Cell 78, 539-542.
5. Harris CC (1996). Structure and function of the p53 tumor suppressor gene: clues for rational cancer therapeutic strategies. J Natl Cancer Inst 88, 1442-1455.
6. Levine A, Perry M, Chang A, Silver A, Dittmer D, Wu M, and Welsh D (1994). The 1993 Walter Hubert lecture: the role of the p53 tumour-suppressor gene in tumorigenesis. Br J Cancer 69, 409-416.
7. Ko LJ, and Prives C (1996). p53: puzzle and paradigm. Genes Dev 10, 1054-1072.
8. Canman C, and Kastan M (1997). Role of p53 in apoptosis. Adv Pnarmacol 41, 429-460.
9. Zhou XL, Wang XW, Xu LX, Hagiwara K, Nagashima M, Wolkowicz R, Zurer I, Rotter V, and Harris CC (1999). COOH-terminal domain of p53 modulates p53-mediated transcriptional transactivation, cell growth, and apoptosis. Cancer Res 59, 843-848.
10. Maltzman W, and Czyzyk L (1984). UV irradiation stimulates levels of p53 cellular antigen in nontransformed mouse cells. Mol Cell Biol 4, 1689-1694.
11. Fritsche M, Haessler C, and Brandner G (1993). Induction of nuclear accumulation of the tumor suppressor protein p53 by DNA-damaging agents. Oncogen 8, 307-318.
12. Hupp T, Meek D, Midgley C, and Lane D (1992). Regulation of the specific DNA binding function of p53. Cell 71, 875-886.
13. Hupp TR (1999). Regulation of p53 protein function through alterations in protein-folding pathways. Cell Mol Life Sci 55, 88-95.
14. Freedman DA, and Levine AJ (1999). Regulation of the p53 protein by the MDM2 oncoprotein - thirty-eighth G.H.A. Clowes Memorial Award lecture. Cancer Res 59, 1-7.
15. Smith ML, and Fornace AJ (1997). p53-mediated protective responses to UV irradiation. Proc Natl Acad Sci USA 94, 12255-12257.
16. Amundson SA, Bittner M, Chen YD, Trent J, Meltzer P, and Fornace AJ (1999). Fluorescent cDNA microarray hybridization reveals complexity and heterogeneity of cellular genotoxic stress responses. Oncogen 18, 3666-3672.
17. Zambetti G, Bargonetti J, Walker K, Prives C, and Levine A (1992). Wild-type p53 mediates positive regulation of gene expression through a specific DNA sequence element. Genes Dev 6, 1143-1152.
18. Farmer G, Bargonetti J, Zhu H, Friedman P, Prywes R, and Prives C (1992). Wild-type p53 activates transcription in vitro. Nature 358, 83-86.
19. Ginsberg D, Mechta F, Yaniv M, and Oren M (1991). Wild-type p53 can downmodulate the activity of various promoters. Proc Natl Acad Sci USA 88, 9979-9983.
20. Seto E, Usheva A, Zambetti G, Momand J, Horikoshi N, Weinmann R, Levine A, and Shenk T (1992). Wild-type p53 binds to the TATA-binding protein and repress transcription. Proc Natl Acad Sci USA 89, 12028-12032.
21. Liu X, and Berk AJ (1995). Reversal of in vitro p53 squelching by both TFIIB and TFIID. Mol Cell Biol 15, 6474-6478.
22. Budde A, and Grummt I (1999). p53 represses ribosomal gene transcription. Oncogene 18, 1119-1124.
23. Murphy M, Ahn J, Walker K, Hoffman W, Evans R, Levine A, and George D (1999). Transcriptional repression by wild-type p53 utilizes histone deacetylases, mediated by interaction with mSin3a. Genes Dev 13, 2490-2501.
24. Harper J, Adami G, Wei N, Keyormarsi K, and Elledge S (1993). The p21 cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 75, 805-816.
25. Dulic V, Kaufmann WK, Wilson SJ, Tlsty TD, Lees E, Harper JW, Elledge SJ, and Reed SI (1994). p53-dependent inhibition of cyclin-dependent kinase activities in human fibroblasts during radiation-induced G1 arrest. Cell 76, 1013-1023.
26. Smith ML, Chen IT, Zhan QM, Oconnor PM, and Fornace AJ (1995). Involvement of the p53 tumor suppressor in repair of UV-type DNA damage. Oncogene 10, 1053-1059.
27. Ford JM, and Hanawalt PC (1995). Li-Fraumeni syndrome fibroblasts homozygous for p53 mutations are deficient in global DNA repair but exhibit normal transcription-coupled repair and enhanced UV resistance. Proc Natl Acad Sci USA 92, 8876-8880.
28. Ford JM, and Hanawalt PC (1997). Expression of wild-type p53 is required for efficient global genomic nucleotide excision repair in UV-irradiated human fibroblasts. J Biol Chem 272, 28073-28080.
29. McKay BC, Francis MA, and Rainbow AJ (1997). Wild-type p53 is required for heat shock and ultraviolet-light-enhanced repair of a UV-damaged reporter gene. Carcinogenesis 18, 245-249.
30. Hwang BJ, Ford JM, Hanawalt PC, and Chu G (1999). Expression of the p48 xeroderma pigmentosum gene is p53-dependent and is involved in global genomic repair. Proc Natl Acad Sci USA 96, 424-428.
31. McKay BC, Ljungman M, and Rainbow AJ (1999). Potential roles for p53 in nucleotide excision repair. Carcinogenesis 20, 1389-1396.
32. Serrano M, Lin AW, McCurrach ME, Beach D, and Lowe SW (1997). Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16(INK4a). Cell 88, 593-602.
33. McKay B, and Ljungman M (1999). Role for p53 in the recovery of transcription and protection against apoptosis induced by ultraviolet light. Neoplasia 1, 276-284.
34. Lowe S, Schmitt E, Smith S, Osborne B, and Jacks T (1993). p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature 362, 847-849.
35. Clarke A, Purdie C, Harrison D, Morris R, Bird C, Hooper M, and Wyllie A (1993). Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature 362, 849-852.
36. Lu X, and Lane DP (1993). Differential induction of transcriptionally active p53 following UV or ionizing radiation - defects in chromosome instability syndromes? Cell 75, 765-778.
37. Soengas MS, Alarcón RM, Yoshida H, Giaccia AJ, Hakem R, Mak TW, and Lowe SW (1999). Apaf-1 and caspase-9 in p53-dependent apoptosis and tumor inhibition. Science 284, 156-159.
38. Miyashita T, and Reed JC (1995). Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 80, 293-299.
39. Owen-Schaub LB, Zhang W, Cusack JC, Angelo LS, Santee SM, Fujiwara T, Roth JA, Deisseroth AB, Zhang WW, Kruzel E, et al. (1995). Wild-type human p53 and a temperature-sensitive mutant induce Fas/APO-1 expression. Mol Cell Biol 15, 3032-3040.
40. Wu GS, Burns TF, McDonald ER, Jiang W, Meng R, Krantz ID, Kao G, Gan DD, Zhou JY, Muschel R, Hamilton SR, Spinner NB, Markowitz S, Wu G, and ElDeiry WS (1997). KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor gene. Nat Genet 17, 141-143.
41. Haupt Y, Rowan S, Shaulian E, Vousden KH, and Oren M (1995). Induction of apoptosis in HeLa cells by transactivation-deficient p53. Gene Dev 9, 2170-2183.
42. Johnson TM, Yu ZX, Ferrans VJ, Lowenstein RA, and Finkel T (1996). Reactive oxygen species are downstream mediators of p53-dependent apoptosis. Proc Natl Acad Sci USA 93, 11848-11852.
43. Polyak K, Xia Y, Zweier JL, Kinzler KW, and Vogelstein B (1997). A model for p53-induced apoptosis. Nature 389, 300-305.
44. Li P-F, Dietz R, and von Harsdorf R (1999). p53 regulates mitochondrial membrane potential through reactive oxygen species and induces cytochrome c-independent apoptosis blocked by Bcl-2. EMBO J 18, 6027-6036.
45. Bennett M, Macdonald K, Chan SW, Luzio JP, Simari R, and Weissberg P (1998). Cell surface trafficking of Fas: a rapid mechanism of p53-mediated apoptosis. Science 282, 290-293.
46. Rehemtulla A, Hamilton CA, Chinnaiyan AM, and Dixit VM (1997). Ultraviolet-radiation-induced apoptosis is mediated by activation of CD-95 (Fas/APO-1). J Biol Chem 272, 25783-25786.
47. Hill LL, Ouhtit A, Loughlin SM, Kripke ML, Ananthaswamy HN, and Owen-Schaub LB (1999). Fas ligand: a sensor for DNA damage critical in skin cancer etiology. Science 285, 898-900.
48. Chinnaiyan A (1999). The apoptosome: heart and soul of the cell death machine. Neoplasia 1, 5-15.
49. Nuñez G, Benedict M, Hu Y, and Inohara N (1998). Caspases: the proteases of the apoptotic pathway. Oncogene 17, 3237-3245.
50. Sionov R, and Haupt Y (1999). The cellular response to p53: the decision between life and death. Oncogene 18, 6145-6157.
51. Scheffner M, Werness B, Huibregtse J, Levine A, and Howley P (1990). The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 1129-1136.
52. Chowdary D, Dermody J, Jha K, and Ozer H (1994). Accumulation of p53 in a mutant cell line defective in the ubiquitin pathway. Mol Cell Biol 14, 1997-2003.
53. Maki CG, Huibregtse JM, and Howley PM (1996). In vivo ubiquitination and proteasome-mediated degradation of p53. Cancer Res 56, 2649-2654.
54. Maki CG, and Howley PM (1997). Ubiquitination of p53 and p21 is differentially affected by ionizing and UV radiation. Mol Cell Biol 17, 355-363.
55. Brown J, and Pagano M (1997). Mechanism of p53 degradation. Biochim Biophys Acta 1332, O1-O6.
56. Varshavsky A (1997). The ubiquitin system. Trends Biochem Sci 22, 383-387.
57. Hilt W, and Wolf DH (1996). Proteasomes: destruction as a programme. Trends Biochem Sci 21, 96-102.
58. Koepp D, Harper J, and Elledge S (1999). How the cyclin became a cyclin: regulated proteolysis in the cell cycle. Cell 97, 431-434.
59. Coux O, Tanaka K, and Goldberg A (1996). Structure and functions of the 20S and 26S proteosomes. Annu Rev Biochem 65, 801-847.
60. Haupt Y, Maya R, Kazaz A, and Oren M (1997). Mdm2 promotes the rapid degradation of p53. Nature 387, 296-299.
61. Kubbutat MHG, Jones SN, and Vousden KH (1997). Regulation of p53 stability by Mdm2. Nature 387, 299-303.
62. Honda R, Tanaka H, and Yasuda H (1997). Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett 420, 25-27.
63. Fuchs SY, Adler V, Buschmann T, Wu XW, and Ronai Z (1998). Mdm2 association with p53 targets its ubiquitination. Oncogene 17, 2543-2547.
64. Kubbutat M, Ludwig R, Ashcroft M, and Vousden K (1998). Regulation of Mdm2-directed degradation by the C-terminus of p53. Mol Cell Biol 18, 5690-5698.
65. Midgley CA, and Lane DP (1997). p53 protein stability in tumour cells is not determined by mutation but is dependent on Mdm2 binding. Oncogene 15, 1179-1189.
66. Fuchs SY, Adler V, Buschmann T, Yin ZM, Wu XW, Jones SN, and Ronai Z (1998). JNK targets p53 ubiquitination and degradation in nonstressed cells. Genes Dev 12, 2658-2663.
67. Fuchs SY, Fried VA, and Ronai Z (1998). Stress-activated kinases regulate protein stability. Oncogene 17, 1483-1490.
68. Kubbutat MHG, and Vousden KH (1997). Proteolytic cleavage of human p53 by calpain: a potential regulator of protein stability. Mol Cell Biol 17, 460-468.
69. Pariat M, Carillo S, Molinari M, Salvat C, Debussche L, Bracco L, Milner J, and Piechaczyk M (1997). Proteolysis by calpains: a possible contribution to degradation of p53. Mol Cell Biol 17, 2806-2815.
70. Gonen H, Shkedy D, Barnoy S, Kosower NS, and Ciechanover A (1997). On the involvement of calpains in the degradation of the tumor suppressor protein p53. FEBS Lett 406, 17-22.
71. Ljungman M, Zhang FF, Chen F, Rainbow AJ, and McKay BC (1999). Inhibition of RNA polymerase II as a trigger for the p53 response. Oncogene 18, 583-592.
72. Yamaizumi M, and Sugano T (1994). UV-induced nuclear accumulation of p53 is evoked through DNA damage of actively transcribed genes independent of the cell cycle. Oncogene 9, 2775-2784.
73. Ljungman M, and Zhang F (1996). Blockage of RNA polymerase as a possible trigger for UV light-induced apoptosis. Oncogene 13, 823-831.
74. Dumaz N, Duthu A, Ehrhart JC, Drougard C, Appella E, Anderson CW, May P, Sarasin A, and DayaGrosjean L (1997); Prolonged p53 protein accumulation in trichothiodystrophy fibroblasts dependent on unrepaired pyrimidine dimers on the transcribed strands of cellular genes. Mol Carcinogen 20, 340-347.
75. McKay BC, Ljungman M, and Rainbow AJ (1998). Persistent DNA damage induced by ultraviolet light inhibits p21 (waf1) and bax expression: implications for DNA repair, UV sensitivity and the induction of apoptosis. Oncogene 17, 545-555.
76. Sauerbier W, and Hercules K (1978). Gene and transcription mapping by radiation effects. Annu Rev Genet 12, 329-363.
77. Selby C, and Sancar A (1990). Transcription preferentially inhibits nucleotide excision repair of the template DNA strand in vitro. J Biol Chem 265, 21330-21336.
78. Donahue BA, Yin S, Taylor JS, Reines D, and Hanawalt PC (1994). Transcript cleavage by RNA polymerase II arrested by a cyclobutane pyrimidine dimer in the DNA template. Proc Natl Acad Sci USA 91, 8502-8506.
79. Roy R, Adamczewski JP, Seroz T, Vermeulen W, Tassan JP, Schaeffer L, Nigg EA, Hoeijmakers JHJ, and Egly JM (1994). The MO15 cell cycle kinase is associated with the TFIIH transcription DNA repair factor. Cell 79, 1093-1101.
80. Ko LJ, Shieh SY, Chen XB, Jayaraman L, Tamai K, Taya Y, Prives C, and Pan ZQ (1997). p53 is phosphorylated by CDK7-cyclin H in a p36(MAT1)-dependent manner. Mol Cell Biol 17, 7220-7229.
81. Lu H, Fisher RP, Bailey P, and Levine AJ (1997). The CDK7-cycH-p36 complex of transcription factor IIH phosphorylates p53, enhancing its sequence-specific DNA binding activity in vitro. Mol Cell Biol 17, 923-5934.
82. Dikstein R, Ruppert S, and Tjian R (1996). TAFII250 is a bipartite protein kinase that phosphorylates the basal transcription factor RAP74. Cell 84, 81-790.
83. Mizzen CA, Yang XJ, Kokubo T, Brownell JE, Bannister AJ, OwenHughes T, Workman J, Wang L, Berger SL, Kouzarides T, Nakatani Y, and Allis CD (1996). The TAF(II)250 subunit of TFIID has histone acetyltransferase activity. Cell 87, 261-1270.
84. Léveillard T, and Wasylyk B (1997). The MDM2 C-terminal region binds to TAF (II) 250 and is required for MDM2 regulation of the cyclin A promoter. J Biol Chem 272, 30651-30661.
85. Gu W, and Roeder RG (1997). Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain. Cell 90, 595-606.
86. Sakaguchi K, Herrera JE, Saito S, Miki T, Bustin M, Vassilev A, Anderson CW, and Appella E (1998). DNA damage activates p53 through a phosphorylation-acetylation cascade. Genes Dev 12, 2831-2841.
87. Brasch K (1990). Drug and metabolite-induced perturbations in nuclear structure and function: a review. Biochem Cell Biol 68, 408-426.
88. Haaf T, and Ward DC (1996). Inhibition of RNA polymerase II transcription causes chromatin decondensation, loss of nucleolar structure, and dispersion of chromosomal domains. Exp Cell Res 224, 163-173.
89. Blattner C, Sparks A, and Lane D (1999). Transcription factor E2F-1 is upregulated in response to DNA damage in a manner analogous to that of p53. Mol Cell Biol 19, 3704-3713.
90. Hutchinson F (1985). Chemical changes induced in DNA by ionizing radiation. Prog Nucleic Acids Res Mol Biol 32, 115-154.
91. Ward JF (1988). DNA damage produced by ionizing radiation in mammalian cells: identities, mechanisms of formation, and repair-ability. Prog Nucleic Acids Res Mol Biol 35, 95-125.
92. Ljungman M (1999). Repair of radiation-induced DNA strand breaks does not occur preferentially in transcriptionally active DNA. Radiat Res 152, 444-449.
93. Bohr VA, Smith CL, Okumoto DS, and Hanawalt PC (1985). DNA repair in an active gene: removal of pyrimidine dimers from the DHFR gene of CHO cells is much more efficient than in the genome overall. Cell 40, 359-369.
94. Kastan M, Onyekwere O, Sidransky D, Vogelstein B, and Craig R (1991). Participation of p53 protein in the cellular response to DNA damage. Cancer Res 51, 6304-6311.
95. Nelson WG, and Kastan MB (1994). DNA strand breaks: the DNA template alterations that trigger p53-dependent DNA damage response pathways. Mol Cell Biol 14, 1815-1823.
96. Ljungman M, and Hanawalt PC (1992). Localized torsional tension in the DNA of human cells. Proc Natl Acad Sci USA 89, 6055-6059.
97. Ljungman M, and Hanawalt P (1995). Presence of negative torsional tension in the promoter region of the transcriptionally poised dihydrofolate reductase gene in vivo. Nucleic Acids Res 23, 1782-1789.
98. Smilenov LB, Dhar S, and Pandita TK (1999). Altered telomere nuclear matrix interactions and nucleosomal periodicity in ataxia telangiectasia cells before and after ionizing radiation treatment. Mol Cell Biol 19, 6963-6971.
99. Huang LC, Clarkin KC, and Wahl GM (1996). Sensitivity and selectivity of the DNA damage sensor responsible for activating p53-dependent G (1) arrest. Proc Natl Acad Sci USA 93, 4827-4832.
100. Gong JG, Costanzo A, Yang HQ, Melino G, Kaelin WG, Levrero M, and Wang JYJ (1999). The tyrosine kinase c-AbI regulates p73 in apoptotic response to cisplatin-induced DNA damage. Nature 399, 806-809.
101. Agami R, Blandino G, Oren M, and Shaul Y (1999). Interaction of c-AbI and p73 alpha and their collaboration to induce apoptosis. Nature 399, 809-813.
102. Yuan ZM, Shioya H, Ishiko T, Sun XG, Gu JJ, Huang YY, Lu H, Kharbanda S, Weichselbaum R, and Kufe D (1999). P73 is regulated by tyrosine kinase c-AbI in the apoptotic response to DNA damage. Nature 399, 814-817.
103. Sionov RV, Moallem E, Berger M, Kazaz A, Gerlitz O, Ben-Neriah Y, Oren M, and Haupt Y (1999). c-AbI neutralizes the inhibitory effect of Mdm2 on p53. J Biol Chem 274, 8371-8374.
104. Shafman TD, Saleem A, Kyriakis J, Weichselbaum R, Kharbanda S, and Kufe DW (1995). Defective induction of stress-activated protein kinase activity in ataxia telangiectasia cells exposed to ionizing radiation. Cancer Res 55, 3242-3245.
105. Waterman M, Stavridi E, Waterman J, and Halazonetis T (1998). ATM-dependent activation of p53 involves dephosphorylation and association with 14-3-3 proteins. War Genet 19, 175-178.
106. Rock K, Gramm C, Rothstein L, Clark K, Stein R, Dick L, Hwang D, and Goldberg A (1994). Inhibitors of the proteosome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules. Cell 78, 761-771.
107. Glockzin S, von Knethen A, Scheffner M, and Brune B (1999). Activation of the cell death program by nitric oxide involves inhibition of the proteasome. J Biol Chem 274, 19581-19586.
108. Damalas A, Ben-Ze'ev A, Simcha I, Shtutman N, Leal JFN, Zhurinsky J, Geiger B, and Oren M (1999). Excess beta-catenin promotes accumulation of transcriptionally active p53. EMBO J 18, 3054-3063.
109. Corda Y, Anin MF, Leng M, and Job D (1993). Spectrum of DNA-platinum adduct recognition by prokaryotic and eukaryotic DNA-dependent RNA polymerases. Biochemistry 32, 8582-85884.
110. Mello JA, Lippard SJ, and Essigmann JM (1995). DNA adducts of cis-diamminedichloroplatinum(II) and its trans-isomer inhibit RNA polymerase II differentially in vivo. Biochemistry 34, 14783-14791.
111. Hickman MJ, and Samson LD (1999). Role of DNA mismatch repair and p53 in signaling induction of apoptosis by alkylating agents. Proc Natl Acad Sci USA 96, 10764-10769.
112. Kastan MB, Zhan QM, Eldeiry WS, Carrier F, Jacks T, Walsh WV, Plunkett BS, Vogelstein B, and Fornace AJ (1992). A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia telangiectasia. Cell 71, 587-597.
113. Jongmans W, Vuillaume M, Chrzanowska K, Smeets D, Sperling K, and Hall J (1997). Nijmegen breakage syndrome cells fail to induce the p53-mediated DNA damage response following exposure to ionizing radiation. Mol Cell Biol 17, 5016-5022.
114. Camey J, Maser R, Olivares H, Davis E, Le Beau M, Yates J III, Hays L, Morgan W, and Petrini J (1998). The hMre11/hRad50 protein complex and Nijmegen breakage syndrome: linkage of double-strand break repair to cellular DNA damage response. Cell 93, 477-486.
115. Khanna KK, and Lavin MF (1993). Ionizing radiation and UV induction of p53 by different pathways in ataxia telangiectasia cells. Oncogene 8, 3307-3312.
116. Cortez D, Wang Y, Qin J, and Elledge S (1999). Requirement of ATM-dependent phosphorylation of Brca-1 in the DNA damage response to double-strand breaks. Science 286, 1162-1166.
117. Smith GCM, Cary RB, Lakin ND, Hann BC, Teo SH, Chen DJ, and Jackson SP (1999). Purification and DNA binding properties of the ataxia telangiectasia gene product ATM. Proc Natl Acad Sci USA 96, 11134-11139.
118. Suzuki K, Kodama S, and Watanabe M (1999). Recruitment of ATM protein to double strand DNA irradiated with ionizing radiation. J Biol Chem 274, 25571-25575.
119. Canman CE, Lim DS, Cimprich KA, Taya Y, Tamai K, Sakaguchi K, Appella E, Kastan MB, and Siliciano JD (1998). Activation of the ATM kinase by ionizing radiation and phosphorylation of p53. Science 281, 1677-1679.
120. Banin S, Moyal L, Shieh SY, Taya Y, Anderson CW, Chessa L, Smorodinsky NI, Prives C, Reiss Y, Shiloh Y, and Ziv Y (1998). Enhanced phosphorylation of p53 by ATN in response to DNA damage. Science 281, 1674-1677.
121. Sarkaria JN, Busby EC, Tibbetts RS, Roos P, Taya Y, Karnitz LM, and Abraham RT (1999). Inhibition of ATM and ATR kinase activities by the radiosensitizing agent, caffeine. Cancer Res 59, 4375-4382.
122. Blasina A, Price BD, Turenne GA, and McGowan CH (1999). Caffeine inhibits the checkpoint kinase ATM. Curr Biol 9, 1135-1138.
123. Lambert PF, Kashanchi F, Radonovich MF, Shiekhattar R, and Brady JN (1998). Phosphorylation of p53 serine 15 increases interaction with CBP. J Biol Chem 273, 33048-33053.
124. Unger T, Sionov RV, Moallem E, Yee CL, Howley PM, Oren M, and Haupt Y (1999). Mutations in serines 15 and 20 of human p53 impair its apoptotic activity. Oncogene 18, 3205-3212.
125. Pise-Masison C, Radonovich M, Sakaguchi K, Appella E, and Brady J (1998). Phosphorylation of p53: a novel pathway for p53 inactivation in human T-cell lymphotropic virus type 1-transformed cells. J Virol 72, 6348-6355.
126. Sarkaria J, Tibbetts R, Busby E, Kennedy A, Hill D, and Abraham R (1998). Inhibition of phosphoinostide 3-kinase related kinases by the radiosenzitizing agent, wortmannin. Cancer Res 58, 4375-4382.
127. Tibbetts RS, Brumbaugh KM, Williams JM, Sarkaria JN, Cliby WA, Shieh SY, Taya Y, Prives C, and Abraham RT (1999). A role for ATR in the DNA damage-induced phosphorylation of p53. Genes Dev 13, 152-157.
128. Wright J, Keegan K, Herendeen D, Bentley N, Carr A, Hoekstra M, and Concannon P (1998). Protein kinase mutants of human ATR increase sensitivity to UV and ionizing radiation and abrogate cell cycle checkpoint control. Proc Natl Acad Sci USA 95, 7445-7450.
129. Cliby WA, Roberts CJ, Cimprich KA, Stringer CM, Lamb JR, Schreiber SL, and Friend SH (1998). Overexpression of a kinase-inactive ATR protein causes sensitivity to DNA-damaging agents and defects in cell cycle checkpoints. EMBO J 17, 159-169.
130. Lakin N, Hann B, and Jackson S (1999). The ataxia telangiectasia related protein ATR mediates DNA-dependent phosphorylation of p53. Oncogene 18, 3989-3995.
131. Jayaraman L, and Prives C (1999). Covalent and noncovalent modifiers of the p53 protein. Cell Mol Life Sci 55, 76-87.
132. Kachnic LA, Wu B, Wunsch H, Mekeel KL, DeFrank JS, Tang W, and Powell SN (1999). The ability of p53 to activate downstream genes p21WAF1/cip1 and MDM2, and cell cycle arrest following DNA damage is delayed and attenuated in scid cells deficient in the DNA-dependent protein. J Biol Chem 274, 13111-13117.
133. Abraham J, Spaner D, and Benchimol S (1999). Phosphorylation of p53 protein in response to ionizing radiation occurs at multiple sites in both normal and DNA-PK deficient cells. Oncogene 18, 1521-1527.
134. Araki R, Fukumura R, Fujimori A, Taya Y, Shiloh Y, Kurimasa A, Burma S, Li GC, Chen DJ, Sato K, Hoki Y, Tatsumi K, and Abe M (1999). Enhanced phosphorylation of p53 serine 18 following DNA damage in DNA-dependent protein kinase catalytic subunit-deficient cells. Cancer Res 59, 3543-3546.
135. Jimenez GS, Bryntesson F, Torres-Arzayus MI, Priestley A, Beeche M, Saito S, Sakaguchi K, Appella E, Jeggo PA, Taccioli GE, Wahl GM, and Hubank M (1999). DNA-dependent protein kinase is not required for the p53-dependent response to DNA damage. Nature 400, 81-83.
136. Huang LC, Clarkin KC, and Wahl GM (1996). P53-dependent cell cycle arrests are preserved in DNA-activated protein kinase-deficient mouse fibroblasts. Cancer Res 56, 2940-2944.
137. Take Y, Kumano M, Teraoka H, Nishimura S, and Okuyama A (1996). DNA-dependent protein kinase inhibitor (OK-1035) suppresses p21 expression in HCT116 cells containing wild-type p53 induced by adriamycin. Biochem Biophys Res Commun 221, 207-212.
138. Hu MCT, Qiu WR, and Wang YP (1997). JNK1, JNK2 and JNK3 are p53 N-terminal serine 34 kinases. Oncogene 15, 2277-2287.
139. Milne DM, Campbell LE, Campbell DG, and Meek DW (1995). p53 is phosphorylated in vitro and in vivo by an ultraviolet radiation-induced protein kinase characteristic of the c-Jun kinase, JNK1. J Biol Chem 270, 5511-5518.
140. Fuchs SY, Adler V, Pincus MR, and Ronai Z (1998). MEKK1/JNK signaling stabilizes and activates p53. Proc Natl Acad Sci USA 95, 10541-10546.
141. Hibi M, Lin A, Smeal T, Minden A, and Karin M (1993). Identification of an oncoprotein- and UV-responsive protein kinase that binds and potentiates the c-Jun activation domain. Genes Dev 7, 2135-2148.
142. Baskaran R, Wood LD, Whitaker LL, Canman CE, Morgan SE, Xu Y, Barlow C, Baltimore D, Wynshaw-Boris A, Kastan MB, and Wang JYJ (1997). Ataxia telangiectasia mutant protein activates c-AbI tyrosine kinase in response to ionizing radiation. Nature 387, 516-519.
143. Shafman T, Kanna KK, Kedar P, Spring K, Kozlov S, Yen T, Hobson K, Gatei M, Zhang N, Watters D, Egerton M, Shiloh Y, Kharbanda S, Kufe D, and Lavine MF (1997). Interaction between ATM protein and c-AbI in response to DNA damage. Nature 387, 520-523.
144. Kharbanda S, Pandey P, Jin SF, Inoue S, Bharti A, Yuan ZM, Weichselbaum R, Weaver D, and Kufe D (1997). Functional interaction between DNA-PK and c-AbI in response to DNA damage. Nature 386, 732-735.
145. Knippschild U, Milne DM, Campbell LE, DeMaggio AJ, Christenson E, Hoekstra MF, and Meek DW (1997). p53 is phosphorylated In vitro and in vivo by the delta and epsilon isoforms of casein kinase 1 and enhances the level of casein kinase 1 delta in response to topoisomerase-directed drugs. Oncogene 15, 1727-1736.
146. Meek D, Simon S, Kikkawa U, and Eckhart W (1990).The p53 tumor suppressor protein is phosphorylated at serine 389 by casein kinase II. EMBO J 9, 3253-3260.
147. Hall SR, Campbell LE, and Meek DW (1996). Phosphorylation of p53 at the casein kinase II site selectively regulates p53-dependent transcriptional repression but not transactivation. Nucleic Acids Res 24, 1119-1126.
148. Hupp TR, and Lane DP (1995). Two distinct signaling pathways activate the latent DNA binding function of p53 in a casein kinase II-independent manner. J Biol Chem 270, 18165-18174.
149. Filhol O, Baudier J, Chambaz EM, and Cochet C (1996). Casein kinase 2 inhibits the renaturation of complementary DNA strands mediated by p53 protein. Biochem J 316, 331-335.
150. Appel K, Wagner P, Boldyreff B, Issinger O-G, and Montenarh M (1995). Mapping of the interaction sites of the growth suppressor protein p53 with the regulatory b-subunit of protein kinase CK2. Oncogene 11, 1971-1978.
151. Sakaguchi K, Sakamoto H, Lewis MS, Anderson CW, Erickson JW, Appella E, and Xie D (1997). Phosphorylation of serine 392 stabilizes the tetramer formation of tumor suppressor protein p53. Biochemistry 36, 10117-10124.
152. Adamczewski J, Rossignol M, Tassan J-P, Nigg E, Moncollin V, and Egly J-M (1996). MAT1, cdk7 and cyclin H form a complex which is UV light-sensitive upon association with TFIIH. EMBO J 15, 1877-1884.
153. Takenaka I, Morin F, Seizinger BR, and Kley N (1995). Regulation of the sequence-specific DNA binding function of p53 by protein kinase C and protein phosphatases. J Biol Chem 270, 5405-5411.
154. Youmell M, Park S, Basu S, and Price B (1998). Regulation of the p53 protein by protein kinase Cα and protein kinase Cξ. Biochem Biophys Res Commun 245, 514-518.
155. Rusnak JM, and Lazo JS (1996). Downregulation of protein kinase C suppresses induction of apoptosis in human prostatic carcinoma cells. Exp Cell Res 224, 189-199.
156. Milne DM, Mckendrick L, Jardine LJ, Deacon E, Lord JM, and Meek DW (1996). Murine p53 is phosphorylated within the PAb421 epitope by protein kinase C in vitro, but not in vivo, even after stimulation with the phorbol ester o-tetradecanoylphorbol 13-acetate. Oncogene 13, 205-211.
157. Matsui M, and DeLeo V (1990). Induction of protein kinase C activity by ultraviolet radiation. Carcinogenesis 11, 229-234.
158. Bischoff J, Friedman P, Marshak D, Prives C, and Beach D (1990). Human p53 is phosphorylated by p60-cdc2 and cyclin B-cdc2. Proc Natl Acad Sci USA 87, 4766-4770.
159. Stürzbecher H-W, Maimets T, Chumakov P, Brain R, Addison C, Simanis V, Rudge K, Philp R, Grimaldi M, Court W, and Jenkins J (1990). p53 interacts with p34cdc2 in mammalian cells: implications for the cell cycle control and oncogenesis. Oncogene 5, 795-801.
160. Price BD, Hughesdavies L, and Park SJ (1995). cdk2 kinase phosphorylates serine 315 of human p53 in vitro. Oncogene 11, 73-80.
161. Wagner P, Fuchs A, Gotz C, Nastainczyk W, and Montenarh M (1998). Fine mapping and regulation of the association of p53 with p34(Cdc2). Oncogene 16, 105-111.
162. Wang Y, and Prives C (1995). Increased and altered DNA binding of human p53 by S and G2/M but not G1 cyclin-dependent kinases. Nature 376, 88-91.
163. Lin W-C, and Desiderio S (1993). Regulation of V (D) J recombination activator protein RAG-2 by phosphorylation. Science 260, 953-959.
164. Herzinger T, Funk J, Hillmer K, Eick D, Wolf D, and Kind P (1995). Ultraviolet B irradiation-induced G2 cell cycle arrest in human keratinocytes by inhibitory phosphorylation of the cdc2 cell cycle kinase. Oncogene 11, 2151-2156.
165. Poon RYC, Jiang W, Toyoshima H, and Hunter T (1996). Cyclin-dependent kinases are inactivated by a combination of p21 and Thr-14/Tyr-15 phosphorylation after UV-induced DNA damage. J Biol Chem 271, 13283-13291.
166. Poon RYC, Chau MS, Yamashita K, and Hunter T (1997). The role of Cdc2 feedback loop control in the DNA damage checkpoint in mammalian cells. Cancer Res 57, 5168-5178.
167. Huang CS, Ma WY, Maxiner A, Sun Y, and Dong ZG (1999). p38 kinase mediates UV-induced phosphorylation of p53 protein at serine 389. J Biol Chem 274, 12229-12235.
168. Cuddihy AR, Li SY, Tam NWN, Wong AHT, Taya Y, Abraham N, Bell JC, and Koromilas AE (1999). The double-stranded RNA activated protein kinase PKR enhances transcriptional activation by tumor suppressor p53. Mol Cell Biol 19, 2475-2484.
169. Cuddihy AR, Wong AHT, Tam NWN, Li SY, and Koromilas AE (1999). The double-stranded RNA activated protein kinase PKR physically associates with the tumor suppressor p53 protein and phosphorylates human p53 on serine 392 in vitro. Oncogene 18, 2690-2702.
170. Shieh SY, Taya Y, and Prives C (1999). DNA damage-inducible phosphorylation of p53 at N-terminal sites including a novel site, Ser20, requires tetramerization. EMBO J 18, 1815-1823.
171. Unger T, Juven-Gershon T, Moallem E, Berger M, Sionov RV, Lozano G, Oren M, and Haupt Y (1999). Critical role for Ser20 of human p53 in the negative regulation of p53 by Mdm2. EMBO J 18, 1805-1814.
172. Jamal S, and Ziff EB (1995). Raf phosphorylates p53 in vitro and potentiates p53-dependent transcriptional transactivation in vivo. Oncogene 10, 2095-2101.
173. Kasid U, Suy S, Dent P, Ray S, Whiteside TL, and Sturgill TW (1996). Activation of Raf by ionizing radiation. Nature 382, 813-816.
174. Radler-Pohl A, Sachsenmaier C, Gebel S, Auer HP, Bruder JT, Rapp U, Angel P, Rahmsdorf HJ, and Herrlich P (1993). UV-induced activation of AP-1 involves obligatory extranuclear steps including Raf-1 kinase. EMBO J 12, 1005-1012.
175. Devary Y, Gottlieb R, Smeal T, and Karin M (1992). The mammalian ultraviolet response is triggered by activation of Src tyrosine kinase. Cell 71, 1081-1091.
176. Yan Y, Shay JW, Wright WE, and Mumby MC (1997). Inhibition of protein phosphatase activity induces p53-dependent apoptosis in the absence of p53 transactivation. J Biol Chem 272, 15220-15226.
177. Millward T, Zolnierowicz S, and Hemmings B (1999). Regulation of protein kinase cascades by protein phosphatase 2A. Trends Biochem Sci 24, 186-191.
178. WAF1/Cip1 and mediate growth arrest. J Biol Chem 273, 12250-12258.
179. Li L, Emsting B, Wishart M, Lohse D, and Dixon J (1997). A family of putative tumor suppressors is structurally and functionally conserved in humans and yeast. J Biol Chem 272, 29403-29406.
180. Yuan ZM, Huang YY, lshiko T, Nakada S, Utsugisawa T, Shioya H, Utsugisawa Y, Yokoyama K, Weichselbaum R, Shi Y, and Kufe D (1999). Role for p300 in stabilization of p53 in the response to DNA damage. J Biol Chem 274, 1883-1886.
181. Liu L, Scolnick DM, Trievel RC, Zhang HB, Marmorstein R, Halazonetis TD, and Berger SL (1999). p53 sites acetylated in vitro by PCAF and p300 are acetylated in vivo in response to DNA damage. Mol Cell Biol 19, 1202-1209.
182. Yuan ZM, Huang YY, Ishiko T, Nakada S, Utsugisawa T, Shioya H, Utsugisawa Y, Shi Y, Weichselbaum R, and Kufe D (1999). Function for p300 and not CBP in the apoptotic response to DNA damage. Oncogene 18, 5714-5717.
183. Wesierska-Gadek J, Bugajskaschretter A, and Cerni C (1996). ADP-ribosylation of p53 tumor suppressor protein: mutant but not wild-type p53 is modified. J Cell Biochem 62, 90-101.
184. Wesierska-Gadek J, Schmid G, and Cerni C (1996). ADP-ribosylation of wild-type p53 In vitro: binding of p53 protein to specific p53 consensus sequence prevents its modification. Biochem Biophys Res Commun 224, 96-102.
185. Ahnström G, and Ljungman M (1988). Effects of 3-aminobenzamide on the rejoining of DNA-strand breaks in mammalian cells exposed to methyl methanesulphonate; role of poly (ADP-ribose) polymerase. Mutat Res 194, 17-22.
186. Althaus FR, Kleczkowska HE, Malanga M, Müntener CR, Pleschke JM, Ebner M, and Auer B (1999). Poly ADP-ribosylation: a DNA break signal mechanism. Mol Cell Biochem 193, 5-11.
187. Jeggo PA (1997). DNA repair: PARP - another guardian angel? Curr Biol 8, R49-R51.
188. Kumari SR, Mendoza-Alvarez H, and Alvarez-Gonzalez R (1998). Functional interactions of p53 with poly (ADP-ribose) polymerase (PARP) during apoptosis following DNA damage: covalent poly (ADP-ribosyl)ation of p53 by exogenous PARP and noncovalent binding of p53 to the Mr 85,000 proteolytic fragment. Cancer Res 58, 5075-5078.
189. Venkatachalam S, Denissenko M, and Wani AA (1997). Modulation of (±)-anti-BPDE mediated p53 accumulation by inhibitors of protein kinase C and poly(ADP-ribose) polymerase. Oncogene 14, 801-809.
190. Vaziri H, West MD, Allsopp RC, Davison TS, Wu YS, Arrowsmith CH, Poirier GG, and Benchimol S (1997). ATM-dependent telomere loss in aging human diploid fibroblasts and DNA damage lead to the posttranslational activation of p53 protein involving poly (ADP-ribose) polymerase. EMBO J 16, 6018-6033.
191. Wesierska-Gadek J, Wang ZQ, and Schmid G (1999). Reduced stability of regularly spliced but not alternatively spliced p53 protein in PARP-deficient mouse fibroblasts. Cancer Res 59, 28-34.
192. Simbulan-Rosenthal CM, Rosenthal DS, Luo RB, and Smulson ME (1999). Poly (ADP-ribosyl)ation of p53 during apoptosis in human osteosarcoma cells. Cancer Res 59, 2190-2194.
193. Wang XJ, Ohnishi K, Takahashi A, and Ohnishi T (1998). Poly (ADP-ribosyl)ation is required for p53-dependent signal transduction induced by radiation. Oncogene 17, 2819-2825.
194. Whitacre CM, Hashimoto H, Tsai ML, Chatterjee S, Berger SJ, and Berger NA (1995). Involvement of NAD-poly (ADP-ribose) metabolism in p53 regulation and its consequences. Cancer Res 55, 3697-3701.
195. Kirch HC, Flaswinkel S, Rumpf H, Brockmann D, and Esche H (1999). Expression of human p53 requires synergistic activation of transcription from the p53 promoter by AP-1, NF-kappaB and Myc/Max. Oncogene 18, 2728-2738.
196. Furlong EEM, Rein T, and Martin F (1996). YY1 and NF1 both activate the human p53 promoter by alternatively binding to a composite element, and YY1 and E1A cooperate to amplify p53 promoter activity. Mol Cell Biol 16, 5933-5945.
197. Stuart E, Haffner R, Oren M, and Gruss P (1995). Loss of p53 function through PAX-mediated transcriptional repression. EMBO J 14, 5638-5645.
198. Uittenbogaard MN, Giebler HA, Reisman D, and Nyborg JK (1995). Transcriptional repression of p53 by human T-cell leukemia virus type I tax protein. J Biol Chem 270, 28503-28506.
199. Schreiber M, Kolbus A, Piu F, Szabowski A, Möhle-Steinlein U, Tian JM, Karin M, Angel P, and Wagner EF (1999). Control of cell cycle progression by c-Jun is p53-dependent. Genes Dev 13, 607-619.
200. Hudson JM, Frade R, and Bareli M (1995). Wild-type p53 regulates its own transcription in a cell-type specific manner. DNA Cell Biol 14, 759-766.
201. Sun XG, Shimizu H, and Yamamoto KI (1995). Identification of a novel p53 promoter element involved in genotoxic stress-inducible p53 gene expression. Mol Cell Biol 15, 4489-4496.
202. Fu LN, and Benchimol S (1997). Participation of the human p53 3′ UTR in translational repression and activation following gamma-irradiation. EMBO J 16, 4117-4125.
203. Mosner J, Mummenbrauer T, Bauer C, Sczakiel G, Grosse F, and Deppert W (1995). Negative feedback regulation of wild-type p53 biosynthesis. EMBO J 14, 4442-4449.
204. Fu LN, Minden MD, and Benchimol S (1996). Translational regulation of human p53 gene expression. EMBO J 15, 4392-4401.
205. Ju JF, Pedersen-Lane J, Maley F, and Chu E (1999). Regulation of p53 expression by thymidylate synthase. Proc Natl Acad Sci USA 96, 3769-3774.
206. Freedman DA, Wu L, and Levine AJ (1999). Functions of the MDM2 oncoprotein. Cell Mol Life Sci 55, 96-107.
207. Freedman DA, and Levine AJ (1998). Nuclear export is required for degradation of endogenous p53 by MDM2 and human papillomavirus E6. Mol Cell Biol 18, 7288-7293.
208. Mayo LD, Turchi JJ, and Berberich SJ (1997). Mdm-2 phosphorylation by DNA-dependent protein kinase prevents interaction with p53. Cancer Res 57, 5013-5016.
209. Pomerantz J, SchreiberAgus N, Liegeois NJ, Silverman A, Alland L, Chin L, Potes J, Chen K, Orlow I, Lee HW, CordonCardo C, and DePinho RA (1998). The Ink4a tumor suppressor gene product, p19(Arf), interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell 92, 713-723.
210. Zhang YP, Xiong Y, and Yarbrough WG (1998). ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell 92, 725-734.
211. Stott FJ, Bates S, James MC, McConnell BB, Starborg M, Brookes S, Palmero I, Ryan K, Hara E, Vousden KH, and Peters G (1998). The alternative product from the human CDKN2A locus, p14ARF, participates in a regulatory feedback loop with p53 and MDM2. EMBO J 17, 5001-5014.
212. ARF with Mdm2 inhibits ubiquitin ligase activity of Mdm2 for tumor suppressor p53. EMBO J 18, 22-27.
213. ARF. Cell 91, 649-659.
214. Zindy F, Eischen CM, Randle DH, Kamijo T, Cleveland JL, Sherr CJ, and Roussel MF (1998). Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization. Genes Dev 12, 2424-2433.
215. ARF links the tumour suppressor p53 to Ras. Nature 395, 125-126.
216. ARF links the tumour suppressors RB and p53. Nature 395, 124-125.
217. ARF tumor suppressor. Genes Dev 12, 2434-2442.
218. Schmitt C, McCurrach M, de Stanchina E, Wallace-Brodeur R, and Lowe S (1999). INK4a/ARF mutations accelerate lymphomagenesis and promote chemoresistance by disabling p53. Genes Dev 13, 2670-2677.
219. Robertson KD, and Jones PA (1998). The human ARF cell cycle regulatory gene promoter is a CpG island which can be silenced by DNA methylation and downregulated by wild-type p53. Mol Cell Biol 18, 6457-6473.
220. Shieh SY, Ikeda M, Taya Y, and Prives C (1997). DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2. Cell 91, 325-334.
221. Siliciano JD, Canman CE, Taya Y, Sakaguchi K, Appella E, and Kastan MB (1997). DNA damage induces phosphorytation of the amino terminus of p53. Genes Dev 11, 3471-3481.
222. Shaulsky G, Ben-Ze'ev A, and Rotter V (1990). Subcellular distribution of the p53 protein during the cell cycle of Balb/c 3T3 cells. Oncogene 5, 1707-1711.
223. David-Pfeuty T, Chakrani F, Ory K, and Nouviandooghe Y (1996). Cell cycle-dependent regulation of nuclear p53 traffic occurs in one subclass of human tumor cells and in untransformed cells. Cell Growth Differ 7, 1211-1225.
224. Komarova EA, Zelnick CR, Chin D, Zeremski M, Gleiberman AS, Bacus SS, and Gudkov AV (1997). Intracellular localization of p53 tumor suppressor protein in gamma-irradiated cells is cell cycle regulated and determined by the nucleus. Cancer Res 57, 5217-5220.
225. Liang SH, Hong D, and Clarke MF (1998). Cooperation of a single lysine mutation and a C-terminal domain in the cytoplasmic sequestration of the p53 protein. J Biol Chem 273, 19817-19821.
226. Liang SH, and Clarke MF (1999). The nuclear import of p53 is determined by the presence of a basic domain and its relative position to the nuclear localization signal. Oncogene 18, 2163-2166.
227. Liang S-H, and Clarke M (1999). A bipartite nuclear localization signal is required for p53 nuclear import regulated by a carboxyl-terminal domain. J Biol Chem 274, 32699-32703.
228. Nigg E (1997). Nucleocytoplasmic transport: signals, mechanisms and regulation. Nature 386, 779-787.
229. Talcott B, and Moore M (1999). Getting across the nuclear pore complex. Trends Cell Biol 9, 312-318.
230. Adam S (1999). Transport pathways of macromolecules between the nucleus and the cytoplasm. Curr Opin Cell Biol 11, 402-406.
231. Stommel JM, Marchenko ND, Jimenez GS, Moll UM, Hope TJ, and Wahl GM (1999). A leucine-rich nuclear export signal in the p53 tetramerization domain: regulation of subcellular localization and p53 activity by NES masking. EMBO J 18, 1660-1672.
232. Moll U, Riou G, and Levine A (1992). Two distinct mechanism alter p53 in breast cancer: mutation and nuclear exclusion. Proc Natl Acad Sci USA 92, 7262-7266.
233. Moll U, LaQuaglia M, Bernard J, and Riou G (1995). Wild-type p53 protein undergoes cytoplasmic sequestration in undifferentiated neuroblastomas but not in differentiated tumors. Proc Natl Acad Sci USA 92, 4407-4411.
234. Ryan J, Prochowink E, Gottlieb C, Apel I, Merino R, Nuñez G, and Clarke M (1994). c-myc and bcI-2 modulate p53 function by altering p53 subcellular trafficking during the cell cycle. Proc Natl Acad Sci USA 91, 5878-5882.
235. Beham A, Marin MC, Fernandez A, Herrmann J, Brisbay S, Tari AM, LopezBerestein G, Lozano G, Sarkiss M, and McDonnell TJ (1997). BcI-2 inhibits p53 nuclear import following DNA damage. Oncogene 15, 2767-2772.
236. Vandromme M, Guuthier-Rouviére C, and Lamb F, A (1996). Regulation of transcription factor localization: fine-tuning of gene expression. Trends Biol Sci 21, 59-64.
237. Hengstermann A, Whitaker NJ, Zimmer D, Zentgraf H, and Scheffner M (1998). Characterization of sequence elements involved in p53 stability regulation reveals cell type dependence for p53 degradation. Oncogene 17, 2933-2941.
238. Blattner C, Tobiasch E, Litten M, Rahmsdorf HJ, and Herrlich P (1999). DNA damage induced p53 stabilization: no indication for an involvement of p53 phosphorylation. Oncogene 18, 1723-1732.
239. Ashcroft M, Kubbutat MHG, and Vousden KH (1999). Regulation of p53 function and stability by phosphorylation. Mol Cell Biol 19, 1751-1758.
240. Visintin R, Craig K, Hwang E, Prinz S, Tyers M, and Amon A (1998). The phosphotase Cdc14 triggers mitotic exit by reversal of Cdk-dependent phosphorylation. Mol Cell 2, 709-718.
241. Hupp T, Sparks A, and Lane D (1995). Small peptides activate the latent sequence-specific DNA binding function of p53. Cell 83, 237-245.
242. Lain S, Midgley C, Sparks A, Lane EB, and Lane DP (1999). An inhibitor of nuclear export activates the p53 response and induces the localization of HDM2 and p53 to U1A-positive nuclear bodies associated with the PODs. Exp Cell Res 248, 457-472.
243. Jayaraman L, Murthy KGK, Zhu C, Curran T, Xanthoudakis S, and Prives C (1997). Identification of redox/repair protein Ref-1 as a potent activator of p53. Genes Dev 11, 558-570.
244. Jayaraman L, Moorthy NC, Murthy KGK, Manley JL, Bustin M, and Prives C (1998). High mobility group protein-1 (HMG-1) is a unique activator of p53. Genes Dev 12, 462-472.
245. Gu W, Shi XL, and Roeder RG (1997). Synergistic activation of transcription by CBP and p53. Nature 387, 819-823.
246. Lill NL, Grossman SR, Ginsberg D, DeCaprio J, and Livingston DM (1997). Binding and modulation of p53 by p300/CBP coactivators. Nature 387, 823-827.
247. Scolnick DM, Chehab NH, Stavridi ES, Lien MC, Caruso L, Moran E, Berger SL, and Halazonetis TD (1997). CREB-binding protein and p300/CBP-associated factor are transcriptional coactivators of the p53 tumor suppressor protein. Cancer Res 57, 3693-3696.
248. Avantaggiati ML, Ogryzko V, Gardner K, Giordano A, Levine AS, and Kelly K (1997). Recruitment of p300/CBP in p53-dependent signal pathways. Cell 89, 1175-1184.
249. Chen XB, Farmer G, Zhu H, Prywes R, and Prives C (1993). Cooperative DNA binding of p53 with TFIID (TBP) - a possible mechanism for transcriptional activation. Genes Dev 7, 1837-1849.
250. Martin D, Munoz R, Subler M, and Deb S (1993). p53 binds to the TATA-binding protein-TATA complexes. J Biol Chem 268, 13062-13067.
251. Xiao H, Pearson A, Coulombe B, Truant R, Zhang S, Regier JL, Triezenberg SJ, Reinberg D, Flores O, Ingles CJ, and Greenblatt J (1994). Binding of basal transcription factor TFIIH to the acidic activation domains of VP16 and p53. Mol Cell Biol 14, 7013-7024.
252. Léveillard T, Andera L, Bissonnette N, Schaeffer L, Bracco L, Egly JM, and Wasylyk B (1996). Functional interactions between p53 and the TFIIH complex are affected by tumour-associated mutations. EMBO J 15, 1615-1624.
253. Farmer G, Colgan J, Nakatani Y, Manley JL, and Prives C (1996). Functional interaction between p53, the TATA-binding protein (TBP), and TBP-associated factors in vivo. Mol Cell Biol 16, 4295-4304.
254. Gualberto A, and Baldwin AS (1995). p53 and Sp1 interact and cooperate in the tumor necrosis factor-induced transcriptional activation of the HIV-1 long terminal repeat. J Biol Chem 270, 19680-19683.
255. Shikama N, Lee CW, France S, Delavaine L, Lyon J, Krstic-Demonacos M, and La Thangue NB (1999). A novel cofactor for p300 that regulates the p53 response. Mol Cell 4, 365-376.
256. Gobert C, Skladanowski A, and Larsen AK (1999). The interaction between p53 and DNA topoisomerase I is regulated differently in cells with wild-type and mutant p53. Proc Natl Acad Sci USA 96, 10355-10360.
257. Tyrell R (1996). Activation of mammalian gene expression by the UV component of sunlight - from models to reality. BioEssays 18, 139-148.
258. Webster GA, and Perkins ND (1999). Transcriptional cross talk between NF-kappaB and p53. Mol Cell Biol 19, 3485-3495.
259. Wadgaonkar R, Phelps KM, Haque Z, Williams AJ, Silverman ES, and Collins T (1999). CREB-binding protein is a nuclear integrator of nuclear factor-kappaB and p53 signaling. J Biol Chem 274, 1879-1882.
260. Chakravarti D, Ogryzko V, Kao H-Y, Nash A, Chen H, Nakatani Y, and Evans R (1999). A viral mechanism for inhibition of p300 and PCAF acetyl transferase activity. Cell 96, 393-403.
261. Hamamori Y, Sartorelli V, Ogryzko V, Puri P, Wu H-Y, Wang Y, Nakatani Y, and Kedes L (1999). Regulation of histone acetyltransferases p300 and PCAF by the bHLH protein twist and adenoviral oncoprotein E1A. Cell 96, 405-413.
262. Girinsky T, Koumenis C, Graeber TG, Peehl DM, and Giaccia AJ (1995). Attenuated response of p53 and p21 in primary cultures of human prostatic epithelial cells exposed to DNA-damaging agents. Cancer Res 55, 3726-3731.
263. Aladjem MI, Spike BT, Rodewald LW, Hope TJ, Klemm M, Jaenisch R, and Wahl GM (1998). ES cells do not activate p53-dependent stress responses and undergo p53-independent apoptosis in response to DNA damage. Curr Biol 8, 145-155.
264. Meyer KM, Hess SM, Tlsty TD, and Leadon SA (1999). Human mammary epithelial cells exhibit a differential p53-mediated response following exposure to ionizing radiation or UV light. Oncogene 18, 5795-5805.
265. Hamadeh HK, Vargas M, Lee E, and Menzel DB (1999). Arsenic disrupts cellular levels of p53 and mdm2: a potential mechanism of carcinogenesis. Biochem Biophys Res Commun 263, 446-449.
266. Méplan C, Mann K, and Hainaut P (1999). Cadmium induces conformational modifications of wild-type p53 and suppresses p53 response to DNA damage in cultured cells. J Biol Chem 44, 31663-31670.
267. Kress M, May E, Cassingena R, and May P (1979). Simian virus-transformed cells express new species of proteins precipitable by anti-simian virus 40 tumor serum. J Virol 31, 472-483.
268. Lane D, and Crawford L (1979). T antigen is bound to a host protein in SV40-transformed cells. Nature 278, 261-263.
269. Linzer D, and Levine A (1979). Characterization of a 54K dalton cellular SV40 tumour antigen present in SV40 transformed cells and uninfected embryonal carcinoma cells. Cell 17, 43-52.
270. Linke SP, Clarkin KC, Dileonardo A, Tsou A, and Wahl GM (1996). A reversible, p53-dependent G(0)/G(1) cell cycle arrest induced by ribonucleotide depletion in the absence of detectable DNA damage. Genes Dev 10, 934-947.
271. Eller MS, Maeda T, Magnoni C, Atwal D, and Gilchrest BA (1997). Enhancement of DNA repair in human skin cells by thymidine dinucleotides: evidence for a p53-mediated mammalian SOS response. Proc Natl Acad Sci USA 94, 12627-12632.
272. Zhan Q, Carrier F, and Fornace A (1993). Induction of cellular p53 activity by DNA-damaging agents and growth arrest. Mol Cell Biol 13, 4242-4250.
273. Graeber TG, Peterson JF, Tsai M, Monica K, Fornace AJ, and Giaccia AJ (1994). Hypoxia induces accumulation of p53 protein, but activation of a G(1)-phase checkpoint by low-oxygen conditions is independent of p53 status. Mol Cell Biol 14, 6264-6277.
274. Plaumann B, Fritsche M, Rimpler H, Brandner G, and Hess RD (1996). Flavonoids activate wild-type p53. Oncogene 13, 1605-1614.
275. Liu M, Pelling J, Ju J, Chu E, and Brash D (1998). Antioxidant action via p53-mediated apoptosis. Cancer Res 58, 1723-1729.
276. Tishler R, Calderwood S, Coleman C, and Price B (1993). Increases in sequence specific DNA binding by p53 following treatment with chemotherapeutic and DNA damaging agents. Cancer Res 53, 2212-2216.
277. Matsumoto H, Shimura M, Omatsu T, Okaichi K, Majima H, and Ohnishi T (1994). p53 proteins accumulated by heat stress associate with heat shock proteins HSP72/HSC73 in human glioblastoma cells lines. Cancer Lett 87, 39-46.
278. Ohnishi T, Wang X, Ohnishi K, and Takahashi A (1998). p53-dependent induction of WAF1 by cold shock in human glioma cells. Oncogene 16, 1507-1511.
279. Debbas M, and White E (1993). Wild-type p53 mediates apoptosis by E1A which is inhibited by E1B. Genes Dev 7, 546-554.
280. Hsieh J-K, Chan F. O'Connor D, Mittnacht S, Zhong S, and Lu X (1999). Rb regulates the stability and the apoptotic function of p53 via MDM2. Cell 3, 181-193.
281. Bulavin D, Saito S, Hollander M, Sakaguchi K, Anderson C, Appella E, and Fornace A (1999). Phosphorylation of human p53 by p38 kinase coordinates N-terminal Phosphorylation and apoptosis in response to UV irradiation. EMBO J 18, 6845-6854.
282. Chehab NH, Malikzay A, Stavridi ES, and Halazonetis TD (1999). Phosphorylation of Ser-20 mediates stabilization of human p53 in response to DNA damage. Proc Natl Acad Sci USA 96, 13777-13782.
283. Li L, Ljungman M, and Dixon J (2000). The human Cdc14 phosphatases interact with and dephosphorylate the tumor suppressor protein p53. J Biol Chem, 275, 2410-2414.
284. Shinohara K, Tomioka M, Nakano H, Tone S, Ito H, and Kawashima S (1996). Apoptosis induction resulting from proteasome inhibition. Biochem J 317, 385-388.
285. Drexler HCA (1997). Activation of the cell death program by inhibition of proteasome function. Proc Natl Acad Sci USA 94, 855-860.
286. Shieh SY, Ahn J, Tamai K, Taya Y, and Prives C (2000). The human homologs of checkpoint kinases chk1 and cds1 (Chk2) phosphorylate p53 at multiple DNA damage-inducible sites. Genes Dev 14, 289-300.
287. Chehab NH, Malikzay A, Appel M, and Halazonetis TD (2000). Chk2/hCds1 functions as a DNA damage checkpoint in G(1) by stabilizing p53. Genes Dev 14, 278-288.
288. Hirao A, Kong YY, Matsuoka S, Wakeham A, Ruland J, Yoshida H, Liu D, Elledge SJ, and Mak TW (2000). DNA damage-induced activation of p53 by the checkpoint kinase chk2. Science 287, 1824-1827.
289. Tominaga K, Morisaki H, Kaneko Y, Fujimoto A, Tanaka T, Ohtsubo M, Hirai M, Okayama H, Ikeda K, and Nakanishi M (1999). Role of human Cds1 (Chk2) kinase in DNA damage checkpoint and its regulation by p53. J Biol Chem 274, 31463-31467.
290. Lee JS, Collins KM, Brown AL, Lee CH, and Chung JH (2000). hCds1-mediated phosphorylation of BRCA1 regulates the DNA damage response. Nature 404, 201-204.